Physician profile
Jose Castro
NPI 1083792352
$26,914.43
in general payments reported to CMS, 2019-2025
54 companies · $2,328 in 2025
The $2,328 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,826 · 2020: $3,571 · 2021: $4,890 · 2022: $4,379 · 2023: $3,383 · 2024: $3,538 · 2025: $2,328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,139 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,139.45 |
| Education | $109.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,715.32 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $2,773.82 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $2,386.60 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,281.70 | 2019-2025 | Jardiance, Ofev |
| Lilly USA, LLC | $2,169.27 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $1,925.40 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $1,136.67 | 2019-2023 | |
| Abbvie INC. | $1,106.82 | 2021-2025 | Qulipta, Ubrelvy |
| Amgen INC. | $1,029.65 | 2019-2025 | Repatha, Otezla, Otezla |
| Astellas Pharma US INC | $923.40 | 2019-2025 | Veozah, Myrbetriq |
| Biohaven Pharmaceuticals, INC. | $687.61 | 2021 | |
| Janssen Pharmaceuticals, INC | $621.97 | 2019-2022 | |
| Abbott Laboratories | $599.71 | 2021-2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $517.78 | 2019-2025 | Gardasil 9, Capvaxive |
| Esperion Therapeutics, INC. | $422.89 | 2021-2025 | Nexletol |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Castro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.